



## Current Agreements

### Dealdoc

#### **Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain**

AstraZeneca  
Pozen

Oct 01 2007

# Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain

|                           |   |
|---------------------------|---|
| <b>Companies:</b>         | <a href="#">AstraZeneca</a><br><a href="#">Pozen</a>  |
| <b>Announcement date:</b> | Oct 01 2007<br><a href="#">Co-development and licensing agreement for Vimovo (naproxen and esomeprazole combination) for pain</a><br><a href="#">Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain</a>   |
| <b>Related contracts:</b> | <a href="#">First amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain</a><br><a href="#">Second amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain</a> |

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

## Details

|                               |  |
|-------------------------------|--|
| <b>Announcement date:</b>     | Oct 01 2007  |
| <b>Start date:</b>            | Oct 01 2007  |
| <b>Industry sectors:</b>      | Bigpharma<br>Pharmaceutical<br>Drug delivery<br>Musculoskeletal » Arthritis » Osteoarthritis   |
| <b>Therapy areas:</b>         | Musculoskeletal » Arthritis » Rheumatoid arthritis<br>Musculoskeletal » Symptoms » Bone pain<br>Musculoskeletal » Symptoms » Muscular pain |
| <b>Technology types:</b>      | Drug delivery<br>Small molecules   |
| <b>Deal components:</b>       | Co-development<br>Licensing  |
| <b>Stages of development:</b> | Phase III<br>Formulation   |
| <b>Geographic focus:</b>      | Worldwide  |

## Financials

## Termsheet

*Not available.*

## Press Release

*Not available.*

## Filing Data

Not available.

**Contract**

October 1, 2007

By Facsimile: (919) 913-1039

Gilda Thomas

Senior Vice President & General Counsel

POZEN, Inc.

1414 Raleigh Road, Suite 400

Chapel Hill, NC 27517

USA

Re: Amendment No. 1 dated as of September 6, 2007 (the "Amendment") to the Collaboration and License Agreement dated as of August 1, 2006 by and between POZEN INC. and AstraZeneca AB (the "Agreement")

Dear Gilda:

As you discussed with our counsel, David McIntosh of Ropes & Gray, due to a clerical error in preparing the Amendment, Exhibit G in the executed version of the Amendment was incomplete. Attached to this letter is the complete version of Exhibit G that should have been attached to the Amendment.

If this new Exhibit G attached to this letter is acceptable to Pozen, please execute this letter memorializing the parties' agreement that this new Exhibit G will replace the Exhibit G attached to the executed Amendment. Accordingly, upon execution of this letter, this new attached Exhibit G will become Exhibit G to the Amendment, and the Exhibit G originally attached to the Amendment will be superseded and replaced and be of no further force and effect.

Except as otherwise expressly provided in this letter, the terms of the Agreement shall remain in full force and effect. This letter may be executed in counterparts, each of which when so executed and delivered shall be an original, and all of which together shall constitute one instrument.

[This space left intentionally blank]

\*\*\* Portion for which confidential treatment requested.

- 1 -

-----  
If this letter reflects your understanding, please countersign in the space provided below and return one original copy to my attention by facsimile at (302) 885-6862.

Sincerely,

By: /s/ Richard J. Kenny

Name: Richard J. Kenny

Title: Assistant General Counsel

AGREED:

POZEN INC.

By: /s/ Gilda Thomas

Name: Gilda Thomas

Title: Senior Vice President & General Counsel

\*\*\* Portion for which confidential treatment requested.

-----  
EXHIBIT G

OPERATING PRINCIPLES

GPT Meetings:

\*\*\*

\*\*\*

\*\*\*

CPT Meetings:

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\*

Face-to-Face GPT Meetings:

\*\*\*

\*\*\*

Regulatory:

\*\*\*

\*\*\*

\*\*\*

\*\*\*

\*\*\* Portion for which confidential treatment requested.